KSCC業績集 論文

1.
A prospective study of XELIRI plus bevacizumab as a first‑line therapy in Japanese patients with unresectable or recurrentcolorectal cancer (KSCC1101)
Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H8, Shimose T, Shimokawa M, Saeki H1, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2017 May 19. doi: 10.1007/s10147-017-1140-z. [Epub ahead of print]
PMID:28526907

https://www.ncbi.nlm.nih.gov/pubmed/28526907

2.
Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.
Minami K, Morita M, Emi Y, Okamoto M, Tanaka E, Nagata S, Touyama T, Ohgaki K, Tanaka T, Okumura H, Suenaga T, Tokunaga S, Oki E, Kakeji Y, Akagi Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC)..
Int J Clin Oncol. 2017 Jan 18. doi: 10.1007/s10147-017-1088-z. [Epub ahead of print]
PMID: 28101757

https://www.ncbi.nlm.nih.gov/pubmed/28101757

3.
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer.
Cancer Chemother Pharmacol. 2017 Jan;79(1):147-153. doi: 10.1007/s00280-016-3204-6.
PMID: 27942930

https://www.ncbi.nlm.nih.gov/pubmed/27942930

4.
Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes.
Nitta H, Shimose T, Emi Y, Imamura T, Ohnishi K, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Higashi H, Tsuji A, Akagi Y, Oki E, Maehara Y, Baba H; Kyushu Study Group of Clinical Cancer (KSCC) ancillary study.
Med Oncol. 2016 Nov;33(11):118. doi: 10.1007/s12032-016-0834-9. Epub 2016 Sep 29.
PMID: 27688239

https://www.ncbi.nlm.nih.gov/pubmed/27688239

5.
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Cancer Chemother Pharmacol. 2016 Jul 28. [Epub ahead of print]
PMID:27468920

http://www.ncbi.nlm.nih.gov/pubmed/27468920

6.
Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302).
Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Ishigami S, Tsuji A, Higashi H, Nakamura T, Saeki H, Shirabe K, Kakeji Y, Sakai K, Baba H, Nishimaki T, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer.
Gastric Cancer. 2016 Jul;19(3):968-76. doi: 10.1007/s10120-015-0530-z. Epub 2015 Aug 11.
PMID: 26260876

http://www.ncbi.nlm.nih.gov/pubmed/26260876

7.
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, Sadanaga N, Kusumoto T, Touyama T, Kimura M, Baba H, Akagi Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2016 Apr;21(2):335-43. doi: 10.1007/s10147-015-0895-3. Epub 2015 Sep 4.
PMID: 26338269

http://www.ncbi.nlm.nih.gov/pubmed/26338269

8.
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Takatsuki M, Tokunaga S, Uchida S, Sakoda M, Shirabe K, Beppu T, Emi Y, Oki E, Ueno S, Eguchi S, Akagi Y, Ogata Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Eur J Surg Oncol. 2016 Feb;42(2):184-9. doi: 10.1016/j.ejso.2015.11.007. Epub 2015 Nov 22.
PMID: 26683263

http://www.ncbi.nlm.nih.gov/pubmed/26683263

9.
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Miwa K, Oki E, Emi Y, Saeki H, Kusumoto T, Akagi Y, Ogata Y, Samura H, Tokunaga S, Ishikawa H, Tanaka T, Sueyoshi S, Higashi H, Matsuda H, Touyama T, Maehara Y; Kyushu Study Group of Clinical Cancer.
Int J Clin Oncol. 2016 Feb;21(1):110-7. doi: 10.1007/s10147-015-0850-3. Epub 2015 Jun 3.
PMID:26037783

http://www.ncbi.nlm.nih.gov/pubmed/26037783

10.
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y.
Int J Clin Oncol. 2016 Jan 8. [Epub ahead of print]
PMID:26746689

http://www.ncbi.nlm.nih.gov/pubmed/26746689

11.
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Oki E, Emi Y, Miyamoto Y, Kabashima A, Higashi H, Ogata Y, Ikebe M, Saeki H, Tokunaga S, Shirabe K, Beppu T, Uchida S, Takatsuki M, Sakoda M, Eguchi S, Akagi Y, Kakeji Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1067-74. doi: 10.1245/s10434-015-4771-1. Epub 2015 Sep 3.
PMID:26334293

http://www.ncbi.nlm.nih.gov/pubmed/26746689

12.
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Beppu T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, Kuramoto M, Kabashima A,
Takahashi I, Samura H, Eguchi S, Akagi Y, Natsugoe S, Ogata Y, Kakeji Y, Baba H, Maehara Y; Kyushu Study group of Clinical Cancer (KSCC).
Anticancer Res. 2014 Nov;34(11):6655-62.
PMID:25368271[PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/25368271

13.
Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.
Saeki H, Emi Y, Kumashiro R, Otsu H, Kawano H, Ando K, Ida S, Kimura Y, Tokunaga E, Oki E, Morita M, Shimokawa M, Maehara Y.
Surg Today. 2014 Aug;44(8):1457-64. doi: 10.1007/s00595-013-0716-0. Epub 2013 Sep 8.
PMID:24013837[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24013837

14.
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akagi Y, Maehara Y, Baba H; Kyusyu Study Group of Clinical Cancer (KSCC) ancillary study.
Eur J Surg Oncol. 2014 May;40(5):559-66. doi: 10.1016/j.ejso.2013.12.009. Epub 2013 Dec 20.
PMID:24388740[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24388740

15.
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Oki E, Emi Y, Akagi Y, Tokunaga S, Sadanaga N, Tanaka T, Ogata Y, Saeki H, Kakeji Y, Baba H, Nishimaki T, Natsugoe S, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer.
Oncology. 2013;84(4):233-9. doi: 10.1159/000346690. Epub 2013 Jan 31.
PMID:23392220[PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/23392220

16.
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y, Akagi Y, Natsugoe S, Shirouzu K, Tokunaga S, Sirzen F, Maehara Y;
Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2013 Apr;18(2):254-9. doi: 10.1007/s10147-011-0371-7. Epub 2012 Jan 13.
PMID:22240888[PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/22240888

17.
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y, Akagi Y, Natsugoe S, Shirouzu K, Tokunaga S, Sirzen F, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2013 Apr;18(2):254-9. doi: 10.1007/s10147-011-0371-7. Epub 2012 Jan 13.
PMID:22240888[PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/22240888

18.
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
Baba H, Hayashi N, Emi Y, Kakeji Y, Egashira A, Oki E, Shirabe K, Toyama T, Ohga T, Yamamoto M, Hasegawa H, Kohakura F, Higashi H, Niwa K, Fujita F, Ogata Y, Kohnoe S, Inomata M, Samura H, Tokunaga S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Surg Today. 2011 Dec;41(12):1610-6. doi: 10.1007/s00595-011-4589-9. Epub 2011 Oct 4.
PMID:21969193[PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/21969193